E Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$424K	Buy	+44,532	New	+$346K	0.01%	320
2025 Q2	$301K	Buy	33,592 +9,918	+42%	+$92.4K	0.01%	302
2025 Q1	$178K	Buy	23,674 +7,062	+43%	+$57K	0.01%	370
2024 Q4	$125K	Sell	16,612 -7,226	-30%	-$54.9K	0.01%	376
2024 Q3	$181K	Sell	23,838 -4,447	-16%	-$33.8K	0.01%	336
2024 Q2	$175K	Sell	28,285 -45,895	-62%	-$253K	0.01%	298
2024 Q1	$377K	Buy	74,180 +22,863	+45%	+$129K	0.02%	236
2023 Q4	$307K	Buy	51,317 +9,820	+24%	+$56.9K	0.02%	228
2023 Q3	$294K	Sell	41,497 -10,926	-21%	-$78.5K	0.02%	213
2023 Q2	$369K	Buy	52,423 +5,838	+13%	+$46.8K	0.03%	190
2023 Q1	$389K	Buy	46,585 +6,330	+16%	+$60.9K	0.03%	175
2022 Q4	$462K	Buy	40,255 +4,838	+14%	+$60.3K	0.04%	145
2022 Q3	$446K	Sell	35,417 -8,991	-20%	-$116K	0.04%	146
2022 Q2	$470K	Buy	44,408 +27,767	+167%	+$286K	0.04%	154
2022 Q1	$271K	Buy	16,641 +1,756	+12%	+$28.2K	0.01%	233
2021 Q4	$206K	Buy	14,885 +3,536	+31%	+$46.8K	0.01%	256
2021 Q3	$163K	Buy	+11,349	New	+$179K	0.01%	242
2021 Q1	$112K	Buy	+10,970	New	+$113K	0.01%	236